Mohammed H Ahmed

Dr. Mohammed H Ahmed

Institute of Pharmaceutical Sciences, King's College London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Advanced Materials
Verified
Journal Article
Open access
SOStephen J.K. O'NEill
Stephen J.K. O'NEill
ZHZehuan Huang
Zehuan Huang
MAMohammed H Ahmed
Mohammed H Ahmed
ABAlexander J. Boys
Alexander J. Boys
SVSantiago Velasco‐Bosom
Santiago Velasco‐Bosom
OSOren A. Scherman
Oren A. Scherman
Addressing the mechanical mismatch between biological tissue and traditional electronic materials remains a major challenge in bioelectronics. While rigidity of such materials limits biocompatibility, supramolecular polymer networks can harmoniously interface with biological tissues as they are soft, wet, and stretchable. Here, an electrically conductive supramolecular polymer network that simultaneously exhibits both electronic and ionic conductivity while maintaining tissue‐mimetic mechanical properties, providing an ideal electronic interface with the human body, is introduced. Rational design of an ultrahigh affinity host–guest ternary complex led to binding affinities (>1013 M‐2) of over an order of magnitude greater than previous reports. Embedding these complexes as dynamic cross‐links, coupled with in situ synthesis of a conducting polymer, resulted in electrically conductive supramolecular polymer networks with tissue‐mimetic Young's moduli (500%), rapid self‐recovery and high water content (>84%). Achieving such properties enabled fabrication of intrinsically‐stretchable stand‐alone bioelectrodes, capable of accurately monitoring electromyography signals, free from any rigid materials.

7 September 2023 in Current Opinion in Oncology
Verified
Journal Article
Open access
MAMohammed H Ahmed
Mohammed H Ahmed
MCMichael Canney
Michael Canney
ACAlexandre Carpentier
Alexandre Carpentier
MTMaya Thanou
Maya Thanou
AIAhmed Idbaih
Ahmed Idbaih
Purpose of review: Glioblastoma (GBM), the most prevalent primary brain malignancy in adults, poses significant challenges in terms of treatment. Current therapeutic strategies for GBM patients involve maximal safe resection, followed by radiotherapy with concurrent and adjuvant temozolomide. However, despite this multimodal approach for GBM, the prognosis of GBM patients remains dismal because of their inherent primary and secondary resistances to treatments. Recent findings: Several molecular and cellular mechanisms, including the presence of the blood–brain barrier (BBB), contribute to these resistances. The BBB, comprising multiple layers surrounding brain vessels, acts as a barrier limiting effective drug delivery to the brain. Invasive and noninvasive tools to deliver drugs and pharmaceutical formulations locally or systemically are continuously evolving to overcome the BBB in GBM toward improving drug bioavailability in the brain and reducing systemic toxicities. Summary: Preliminary studies utilizing these approaches have demonstrated promising results in terms of safety and signals of efficacy during early-phase clinical trials. However, further work through additional clinical trials is necessary to evaluate the potential clinical benefits for GBM patients.

30 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMohammed H Ahmed
Mohammed H Ahmed
IHIsaias HERNANDEZ
Isaias HERNANDEZ
EQEmie Quissac
Emie Quissac
NLNolwenn Lemaire
Nolwenn Lemaire
CGCoralie Guerin
Coralie Guerin
Ahmed IdbaihAhmed Idbaih
Ahmed Idbaih
Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood–brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the brain. We explored the safety and the efficacy of UMBO plus immune checkpoint inhibitors in preclinical models of GBM. A blood–brain barrier (BBB) opening was performed using a 1 MHz preclinical ultrasound system in combination with 10 µL/g microbubbles. Brain penetration of immune checkpoint inhibitors was determined, and immune cell populations were evaluated using flow cytometry. The impact of repeated treatments on survival was determined. In syngeneic GL261-bearing immunocompetent mice, we showed that UMBO safely and repeatedly opened the BBB. BBB opening was confirmed visually and microscopically using Evans blue dye and magnetic resonance imaging. UMBO plus anti-PDL-1 was associated with a significant improvement of overall survival compared to anti-PD-L1 alone. Using mass spectroscopy, we showed that the penetration of therapeutic antibodies can be increased when delivered intravenously compared to non-sonicated brains. Furthermore, we observed an enhancement of activated microglia percentage when combined with anti-PD-L1. Here, we report that the combination of UMBO and anti-PD-L1 dramatically increases GL261-bearing mice’s survival compared to their counterparts treated with anti-PD-L1 alone. Our study highlights the BBB as a limitation to overcome in order to increase the efficacy of anti-PD-L1 in GBM and supports clinical trials combining UMBO and in GBM patients.

13 January 2022 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
MAMohammed H Ahmed
Mohammed H Ahmed
IHIsaias Hernández-Verdin
Isaias Hernández-Verdin
FBFranck Bielle
Franck Bielle
MVMaïté Verreault
Maïté Verreault
JLJulie Lerond
Julie Lerond
AIAhmed Idbaih
Ahmed Idbaih
Background: Strategies to modulate the tumor microenvironment (TME) have opened new therapeutic avenues with dramatic yet heterogeneous intertumoral efficacy in multiple cancers, including glioblastomas (GBMs). Therefore, investigating molecular actors of TME may help understand the interactions between tumor cells and TME. Immune checkpoint proteins such as a Cluster of Differentiation 80 (CD80) and CD86 are expressed on the surface of tumor cells and infiltrative tumor lymphocytes. However, their expression and prognostic value in GBM microenvironment are still unclear.Methods: In this study, we investigated, in a retrospective local discovery cohort and a validation TCGA dataset, expression of CD80 and CD86 at mRNA level and their prognostic significance in response to standard of care. Furthermore, CD80 and CD86 at the protein level were investigated in the discovery cohort.Results: Both CD80 and CD86 are expressed heterogeneously in the TME at mRNA and protein levels. In a univariate analysis, the mRNA expression of CD80 and CD86 was not significantly correlated with OS in both local OncoNeuroTek dataset and TCGA datasets. CD80 and CD86 mRNA high expression was significantly associated with shorter progression free survival (PFS) (p < 0.05). These findings were validated using the TCGA cohort; higher CD80 and CD86 expressions were correlated with shorter PFS (p < 0.05). In multivariate analysis, CD86 mRNA expression was an independent prognostic factor for PFS in the TCGA dataset only (p < 0.05).Conclusion: CD86 could be used as a potential biomarker for the prognosis of GBM patients treated with immunotherapy; however, additional studies are needed to validate these findings.

1 January 2021 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
MEMohamed Emara
Mohamed Emara
MAMohammed H Ahmed
Mohammed H Ahmed
AEAmr Elfer
Amr Elfer
AEAyman El-Saka
Ayman El-Saka
AEAsem Elfert
Asem Elfert
SASherief Abd-Elsalam
Sherief Abd-Elsalam
Background and Aims: Human schistosomiasisis one of the most important and unfortunately neglected tropical diseases. The aim of the current study was to investigate the prevalence and characterize colonic schistosomiasis, among symptomatizing rural inhabitants of the Middle Northern region of the Egyptian Nile delta. Patients and Methods: This study recruited 193 inhabitants of the rural community in the Egyptian Nile Delta referred for colonoscopy because of variable symptoms. After giving a written informed consent, they were exposed to thorough history; clinical examination; stool analysis; abdominal ultrasonography, and pan-colonoscopy with biopsies. Results:Twenty-four cases out of the 193 patients had confirmed active schistosomiasis with prevalence rate of 12.4%. Bleeding with stool was the predominant manifestation of active schistosomainfection among the cases either alone or in combination with abdominal pain. On clinical examination, the majority of the patients (n=17; 70.8%)did not have organomegaly and 25% of them had clinically palpable splenomegaly. As far as, 75% of them had sonographically detected hepatic peri-portal fibrosis. Also 66.6% of patients havesignificant endoscopic lesions (polyps, ulcers, mass-like lesions), and 16.6% of them had colonic affection beyond the recto-sigmoid region. Conclusion:Colonic schistosomiasis still running among symptomatizing rural inhabitants of the Egyptian Nile Delta at a rate of 12.4%. Of them66.6% had significant endoscopic colorectal lesions. This persistent transmission of schistosomiasis in the rural community of the Egyptian Nile Delta sounds the alarm for continuing governmental efforts and plans to screen the high-risk groups.

1 October 1999 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
MAMohammed H Ahmed
Mohammed H Ahmed
FAFahad Al-Khodairy
Fahad Al-Khodairy
BKBashir A Khan
Bashir A Khan
MKMohammed Kunhi
Mohammed Kunhi
MHMohammed A Hannan
Mohammed A Hannan